Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Gynecologic 1Endocrine 1CNS 1Breast 1

Conditions

Small Cell Lung Carcinoma 6Neoplasms 4Breast Neoplasms 3Sarcoma 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Mesothelioma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors 2Advanced Solid Tumor 2Stomach Neoplasms 1Solid Tumors 1Recurrence 1Pancreatic Neoplasms 1Mesothelioma, Malignant 1Major Advanced Solid Tumors Other Than Colorectal 1Leukemia 1Glioblastoma 1Gastrointestinal Malignancies 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1ADVANCED SOLID TUMORS 1

Interventions

Fluorouracil 255Leucovorin 224Oxaliplatin 218Irinotecan 206Bevacizumab 200Capecitabine 144Cetuximab 136Panitumumab 68Folfox protocol 63regorafenib 50Colonoscopy 44pembrolizumab 42IFL protocol 39Radiotherapy 32Nivolumab 31Drug Therapy 27trifluridine tipiracil drug combination 26Gemcitabine 24Blood Specimen Collection 23Chemotherapy, Adjuvant 20Surveys and Questionnaires 19Celecoxib 19Surgical Procedures, Operative 16durvalumab 15Neoadjuvant Therapy 15Cyclophosphamide 14Cisplatin 14aflibercept 13Standard of Care 13Pemetrexed 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Colorectal Neoplasms × PM 01183 × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT02210364 2016-12-14

Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

PharmaMar

Phase 1 Completed
81 enrolled
BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡